

## PRESS RELEASE

### XY Therapeutics Receives Prestigious Grant

- XY Therapeutics, together with Herlev Hospital and DTU Center for Diagnostics, receives the prestigious Grand Solutions grant from the Danish Innovation Foundation.
- This grant will support the INFRANKL project that will revolutionize infertility treatment by developing innovative therapies for both male and female infertility.
- The project is the accumulation of more than 10 years research within the field of reproductive endocrinology.

**Copenhagen, May 7, 2024.** XY Therapeutics, a clinical stage therapeutic company focused on the development of treatments for infertility, in collaboration with Herlev Hospital and DTU Center for Diagnostics, receives a 9.8MDKK Grand Solution grant from IFD for the INFRANKL project, with the total project being over 13MDKK.

The project will combine the expertise and IP of XY Therapeutics with the newly created translational endocrinology Center at Herlev Hospital and the diagnostic expertise of DTU Healthtech Centre for Diagnostics.

The objective of the project is to develop novel treatment options for infertility. The project will revolutionize infertility treatment through innovative therapies for both male and female infertility, provide effective, accessible, and evidence-based solutions to address the global challenge of infertility and establish lasting collaborations between XY Therapeutics, Herlev Hospital's Reproductive Endocrinology Center, and DTU Healthtech, Centre for Diagnostics. The indications being targeted are:

- Oligospermia and severe oligospermia in males - general male infertility due to low or severely low quality in sperm count and function.
- Azospermia in males - where no functional sperm is present.
- Polycystic ovary syndrome in females - a common hormonal disorder leading to irregular menstrual periods and fertility challenges.
- Premature ovarian failure (POF) in females - condition characterized by the loss of normal ovarian function before the age of 40.

## NOTES FOR EDITORS

### About XY Therapeutics

Based in Copenhagen, Denmark, XY Therapeutics is a clinical stage biopharmaceutical company focused on the development of novel treatments for infertile couples. The company is currently developing treatment for male infertility, and is running a clinical phase 2 trial in infertile men.

### About Infertility

Infertility is a multifaceted indication affecting one in seven couples worldwide. Although there are many underlying reasons for both men and women developing infertile conditions, there exist no treatment for the vast majority of cases. Instead, infertile couples are left with artificial insemination techniques, which are often expensive and furthermore often lead to multiple adverse effects for the female partner.

For further information, please contact:

Lasse Nørregaard, CBO  
Email: [lan@xytherapeutics.dk](mailto:lan@xytherapeutics.dk)